26/06/2024 – Q&A document of the June 26, 2024 Combined General Meeting Download PDF Post navigationPreviousPrevious post:Summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALSNextNext post:AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSRelated PostsAB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024AB Science announces the success of a 5.0 million euros capital increaseSeptember 30, 2024AB Science provides an update on the microtubule program AB8939September 26, 2024AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024September 23, 2024Positive results of the Phase 2 study evaluating masitinib in Covid-19July 8, 2024AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024
AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024September 23, 2024
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALSJune 28, 2024
